Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center

Basit Öğe Kaydı
dc.contributor.authorAk, Naziye
dc.contributor.authorToker, Alper
dc.contributor.authorKara, Murat
dc.contributor.authorOzkan, Berker
dc.contributor.authorUlker, Melike
dc.contributor.authorKaba, Erkan
dc.contributor.authorYegen, Gulcin
dc.date.accessioned2024-03-13T10:33:28Z
dc.date.available2024-03-13T10:33:28Z
dc.date.issued2021
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractBackground: In this study, we aimed to evaluate the factors that contribute to survival outcomes in patients with thymoma treated with multimodal approaches. Methods: A total of 203 patients (105 males, 98 females; median age: 49 years; range, 17 to 77 years) with Masaoka-Koga Stage II-IV thymoma between January 2002 and December 2018 were retrospectively analyzed. Data including diagnosis of myasthenia gravis, diagnosis of diabetes mellitus, disease stage, histological type of tumor, capsule invasion and surgical margin status, lymphadenectomy, adjuvant radiotherapy or chemotherapy, time from surgery to the first day of adjuvant treatment, length of hospital stay, and overall and disease-free survival rates were recorded. Results: Of the patients, 91 had Stage II, 67 had Stage III, and 45 had Stage IV disease. A total of 123 patients (61%) had myasthenia gravis. Seventy-six patients received adjuvant radiotherapy and 48 patients received either neoadjuvant (n=35) or adjuvant (n=25) chemotherapy. Higher disease stage, presence of R1 resection, and treatment with chemotherapy were significant factors for decreased disease-free survival time. Older age, higher disease stage, longer postoperative hospital stay, chemotherapy, and disease recurrence were effective contributors to decreased overall survival time. Adjuvant radiotherapy had a statistically significant positive effect on overall survival only in patients with completely resected Stage IV disease (five-year overall survival: 94.7% vs. 79.1%, respectively; p=0.015). In the multivariate analysis, older age (hazard ratio: 4.26), higher disease stage (hazard ratio: 2.95), and longer hospitalization time (hazard ratio: 3.81) were significant prognostic factors for overall survival. Patients with local recurrence who underwent complete resection had a survival time comparable to non-recurrent patients (p=0.753). Conclusion: For patients with thymoma, higher disease stage, age >= 50 years, longer hospitalization, and need for chemotherapy are associated with worse survival rates. Adjuvant chemotherapy has a positive impact on Stage IV disease. Resection of recurrent lesions has a valuable impact on survival.en_US
dc.identifier.doi10.5606/tgkdc.dergisi.2021.20529
dc.identifier.endpage495en_US
dc.identifier.issn1301-5680
dc.identifier.issue4en_US
dc.identifier.pmid35096446en_US
dc.identifier.scopus2-s2.0-85118620877en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage487en_US
dc.identifier.trdizinid503212en_US
dc.identifier.urihttps://doi.org/10.5606/tgkdc.dergisi.2021.20529
dc.identifier.urihttps://hdl.handle.net/20.500.12662/3961
dc.identifier.volume29en_US
dc.identifier.wosWOS:000709895700009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBaycinar Medical Publ-Baycinar Tibbi Yayinciliken_US
dc.relation.ispartofTurk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal Of Thoracic And Cardiovascular Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAggressive surgeryen_US
dc.subjectchemotherapyen_US
dc.subjectMasaoka-Koga Stagingen_US
dc.subjectradiotherapyen_US
dc.subjectsurvivalen_US
dc.subjectthymomaen_US
dc.titleOutcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer centeren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu